Subsequently, extensive preclinical pharmacological work in mouse and fly models of FXS demonstrated that treatment with mGluR5 negative allosteric modulators (NAMs) improved synaptic, dendrite morphological, and behavioral phenotypes, pointing to the therapeutic potential of mGluR5 NAMs for the treatment of FXS (4). This evidence concerns the gene GRM5 and fragile X syndrome.